JP2010515698A5 - - Google Patents

Download PDF

Info

Publication number
JP2010515698A5
JP2010515698A5 JP2009545143A JP2009545143A JP2010515698A5 JP 2010515698 A5 JP2010515698 A5 JP 2010515698A5 JP 2009545143 A JP2009545143 A JP 2009545143A JP 2009545143 A JP2009545143 A JP 2009545143A JP 2010515698 A5 JP2010515698 A5 JP 2010515698A5
Authority
JP
Japan
Prior art keywords
formula
compound
biphenyl
salt
nitrogen protecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009545143A
Other languages
English (en)
Japanese (ja)
Other versions
JP5715339B2 (ja
JP2010515698A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/000142 external-priority patent/WO2008083967A2/en
Publication of JP2010515698A publication Critical patent/JP2010515698A/ja
Publication of JP2010515698A5 publication Critical patent/JP2010515698A5/ja
Application granted granted Critical
Publication of JP5715339B2 publication Critical patent/JP5715339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009545143A 2007-01-12 2008-01-10 5−ビフェニル−4−アミノ−2−メチルペンタン酸の製造方法 Active JP5715339B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07100451 2007-01-12
EP07100451.9 2007-01-12
PCT/EP2008/000142 WO2008083967A2 (en) 2007-01-12 2008-01-10 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid

Publications (3)

Publication Number Publication Date
JP2010515698A JP2010515698A (ja) 2010-05-13
JP2010515698A5 true JP2010515698A5 (enExample) 2011-03-03
JP5715339B2 JP5715339B2 (ja) 2015-05-07

Family

ID=38124137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545143A Active JP5715339B2 (ja) 2007-01-12 2008-01-10 5−ビフェニル−4−アミノ−2−メチルペンタン酸の製造方法

Country Status (36)

Country Link
US (4) US8115016B2 (enExample)
EP (1) EP2121578B1 (enExample)
JP (1) JP5715339B2 (enExample)
KR (2) KR101560005B1 (enExample)
CN (1) CN101631765B (enExample)
AR (1) AR064842A1 (enExample)
AU (2) AU2008204546B2 (enExample)
BR (1) BRPI0806700A8 (enExample)
CA (1) CA2674291C (enExample)
CL (1) CL2008000077A1 (enExample)
CO (1) CO6251311A2 (enExample)
CY (1) CY1118225T1 (enExample)
DK (1) DK2121578T3 (enExample)
EC (1) ECSP099508A (enExample)
ES (1) ES2602566T3 (enExample)
GT (1) GT200900195A (enExample)
HR (1) HRP20161484T1 (enExample)
HU (1) HUE030695T2 (enExample)
IL (1) IL199492A (enExample)
JO (1) JO3142B1 (enExample)
LT (1) LT2121578T (enExample)
MA (1) MA31284B1 (enExample)
MX (1) MX2009007474A (enExample)
MY (2) MY151993A (enExample)
NZ (1) NZ577910A (enExample)
PE (2) PE20081563A1 (enExample)
PH (1) PH12012502091A1 (enExample)
PL (1) PL2121578T3 (enExample)
PT (1) PT2121578T (enExample)
RU (1) RU2530900C2 (enExample)
SG (1) SG185318A1 (enExample)
SI (1) SI2121578T1 (enExample)
TN (1) TN2009000296A1 (enExample)
TW (1) TWI413638B (enExample)
WO (1) WO2008083967A2 (enExample)
ZA (1) ZA200904311B (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0806700A8 (pt) * 2007-01-12 2019-01-22 Novartis Ag processo
AU2012202949B2 (en) * 2008-01-17 2015-01-22 Novartis Ag Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
AR070176A1 (es) 2008-01-17 2010-03-17 Novartis Ag Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
CN102448928B (zh) 2009-05-28 2014-10-01 诺华股份有限公司 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
CN102574801B (zh) 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
BR112012017869A2 (pt) * 2010-01-22 2019-09-24 Novartis Ag "intermediários dos inibidores da endopeptidase neutraq e método de preparação dos mesmos"
RU2588572C2 (ru) 2010-08-23 2016-07-10 Новартис Аг Способ получения промежуточных соединений для получения ингибиторов nep
SI2609071T1 (sl) 2010-08-23 2017-01-31 Novartis Ag Novi postopek za pripravo intermediatov, uporabnih za izdelavo NEP inhibitorjev
US8673974B2 (en) * 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
AR084290A1 (es) 2010-12-15 2013-05-08 Theravance Inc Inhibidores de neprilisina, metodos para su preparacion e intermediarios utilizados en los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por la inhibicion de nep
CN105061314A (zh) 2010-12-15 2015-11-18 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
JP5959065B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JP5959066B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
EP2714660B1 (en) 2011-05-31 2018-09-26 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
ES2653215T3 (es) 2011-05-31 2018-02-06 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
WO2012166389A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
TWI562986B (en) 2012-02-15 2016-12-21 Theravance Biopharma R&D Ip Llc Process for preparing 4-amino-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-pentanoic acid compounds
JP6088047B2 (ja) 2012-05-31 2017-03-01 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 一酸化窒素ドナーであるネプリライシン阻害剤
RS55967B1 (sr) 2012-06-08 2017-09-29 Theravance Biopharma R&D Ip Llc Inhibitori neprilizina
EP2858650B1 (en) 2012-06-08 2018-11-14 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
PL2882716T3 (pl) 2012-08-08 2017-06-30 Theravance Biopharma R&D Ip, Llc Inhibitory neprylizyny
JP6301371B2 (ja) 2013-02-14 2018-04-11 ノバルティス アーゲー インビボ効力が改善されたnep阻害剤としての置換ビスフェニルブタン酸誘導体
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Nep(中性エンドペプチダーゼ)阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
RS56300B1 (sr) 2013-03-05 2017-12-29 Theravance Biopharma R&D Ip Llc Inhibitori neprilizina
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
RU2016135057A (ru) 2014-01-30 2018-03-12 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Производные 5-бифенил-4-гетероарилкарбониламинопентановой кислоты в качестве ингибиторов неприлизина
JP2017507921A (ja) 2014-01-30 2017-03-23 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ネプリライシン阻害剤
PL3218351T3 (pl) 2014-11-14 2019-12-31 Zentiva K.S. Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377
CN107074744B (zh) * 2014-12-03 2019-06-18 上海翰森生物医药科技有限公司 Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用
CN104557600B (zh) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
KR102640906B1 (ko) 2015-02-11 2024-02-27 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 네프릴리신 저해제로서 (2s,4r)-5-(5''-클로로-2''-플루오로비페닐-4-일)-4-(에톡시옥살릴아미노)-2-히드록시메틸-2-메틸펜타노익산
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
PL3259255T3 (pl) 2015-02-19 2021-07-26 Theravance Biopharma R&D Ip, Llc Kwas (2R,4R)-5-(5'-chloro-2'-fluorobifenyl-4-ilo)-2-hydroksy-4-[(5-metylooksazolo-2-karbonylo)amino]pentanowy
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
CN106187808A (zh) * 2015-05-08 2016-12-07 苏州鹏旭医药科技有限公司 Ahu-377的制备方法、ahu-377中间体及ahu-377中间体的制备方法
CN104926707B (zh) * 2015-05-12 2017-10-27 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN104829514B (zh) * 2015-05-12 2017-10-03 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
WO2016203500A2 (en) * 2015-06-19 2016-12-22 Actavis Group Ptc Ehf. Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
WO2017003483A1 (en) 2015-07-02 2017-01-05 Novartis Ag Sacubitril calcium salts
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105061263B (zh) * 2015-08-11 2017-03-15 苏州楚凯药业有限公司 一种nep抑制剂中间体的制备方法
CN105168205A (zh) * 2015-08-18 2015-12-23 泰力特医药(湖北)有限公司 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法
WO2017033128A1 (en) 2015-08-25 2017-03-02 Novartis Ag Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
CN105130869B (zh) * 2015-09-07 2017-12-26 曾伟 一种Entresto中间体(S)‑5‑(联苯‑4‑羰基)吡咯烷‑2‑酮的合成方法
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
CN105523964B (zh) * 2015-12-09 2017-05-24 苏州楚凯药业有限公司 一种抗心衰药物中间体的制备方法
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
RU2769445C2 (ru) * 2015-12-10 2022-03-31 Новартис Аг Новый способ и новые промежуточные соединения
BR112018011788A2 (pt) 2015-12-11 2018-12-04 Zentiva Ks formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
CN106977415B (zh) * 2016-01-15 2021-03-26 广东东阳光药业有限公司 一种沙库必曲的中间体及其制备方法
CN105566194A (zh) * 2016-02-01 2016-05-11 张伯引 一种Sacubitril中间体的制备方法
WO2017148357A1 (zh) * 2016-02-29 2017-09-08 广东东阳光药业有限公司 一种沙库必曲的中间体及其制备方法
KR20220035991A (ko) 2016-03-08 2022-03-22 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 (2s,4r)-5-(5'-클로로-2'-플루오로-[1,1'-비페닐]-4-일)-2-(에톡시메틸)-4-(3-히드록시이속사졸-5-카르복사미도)-2-메틸펜탄산 결정 및 그 용도
WO2017191620A1 (en) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A crystalline form of a salt of sacubitril and a process of its preparation
CN105924355B (zh) * 2016-05-11 2018-08-17 浙江宏元药业有限公司 沙库比曲中间体及沙库比曲中间体和沙库比曲的制备方法
US20190256454A1 (en) * 2016-07-05 2019-08-22 Novartis Ag New process for early sacubitril intermediates
CN107602399B (zh) * 2016-07-11 2020-09-25 江西东邦药业有限公司 一种脑啡肽酶抑制剂中间体的制备方法
CN109563019A (zh) * 2016-08-17 2019-04-02 诺华股份有限公司 Nep抑制剂合成的新方法和中间体
CN106496055A (zh) * 2016-10-09 2017-03-15 杭州科巢生物科技有限公司 一种抗心衰新药的关键组分沙库比曲的新合成方法
EP3522886A4 (en) * 2016-10-10 2020-02-19 Laurus Labs Limited STABLE AMORPHE FORM OF THE SACUBITRIL VALSARTAN TRINATRIUM COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
JP7138106B2 (ja) 2016-12-23 2022-09-15 ノバルティス アーゲー 初期サクビトリル中間体のための新規な方法
CN107311909A (zh) * 2017-06-22 2017-11-03 东南大学 一种lcz696杂质对照品的制备方法
CN109206419B (zh) * 2017-06-29 2023-07-14 上海迪赛诺化学制药有限公司 沙库比曲中间体及其制备方法和应用
ES2924880T3 (es) 2017-12-05 2022-10-11 Basf Se Sales orgánicas de ácido sulfónico de ésteres de aminoácidos y procedimiento para su preparación
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN110407733A (zh) * 2018-04-26 2019-11-05 鲁南制药集团股份有限公司 一种沙库巴曲杂质化合物
CN110551151A (zh) * 2018-05-30 2019-12-10 微宏动力系统(湖州)有限公司 一种磷酸酯或亚磷酸酯的制备方法、电解液及二次电池
CN108727213B (zh) * 2018-06-29 2021-06-08 中国科学院上海有机化学研究所 一种沙库必曲的制备方法
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN109456212A (zh) * 2018-12-03 2019-03-12 康化(上海)新药研发有限公司 一种沙库比曲中间体的合成方法
CN109400504A (zh) * 2018-12-11 2019-03-01 重庆三圣实业股份有限公司 Lcz696中间体非对映异构体的分离纯化方法
WO2020144030A1 (en) 2019-01-08 2020-07-16 Basf Se Process for the preparation of organosulfate salts of amino acids esters
CN109912486B (zh) * 2019-04-25 2022-09-27 东北制药集团股份有限公司 一种联苯甲基内酰胺化合物的制备方法
CN110878039A (zh) * 2019-12-18 2020-03-13 株洲千金药业股份有限公司 一种沙库巴曲缬沙坦钠杂质的制备方法
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
BR112023000293A2 (pt) 2020-07-09 2023-03-21 Advansix Resins & Chemicals Llc Tensoativos de aminoácidos ramificados
WO2022015606A1 (en) 2020-07-13 2022-01-20 Advansix Resins & Chemicals Llc Branched amino acid surfactants for cleaning products
KR20250073513A (ko) 2020-07-13 2025-05-27 어드밴식스 레진즈 앤드 케미컬즈 엘엘씨 전자기기 제품을 위한 분지형 아미노산 계면활성제
JP7569921B2 (ja) 2020-07-13 2024-10-18 アドバンシックス・レジンズ・アンド・ケミカルズ・リミテッド・ライアビリティ・カンパニー インク、塗料、及び接着剤のための分岐鎖状アミノ酸界面活性剤
BR112023000521A2 (pt) 2020-07-13 2023-01-31 Advansix Resins & Chemicals Llc Tensoativos de aminoácidos ramificados para uso em produtos de cuidados com a saúde
MX2023000606A (es) 2020-07-13 2023-02-13 Advansix Resins & Chemicals Llc Tensioactivos derivados de aminoacidos ramificados para productos de cuidado personal y cosmeticos.
EP4179038A1 (en) 2020-07-13 2023-05-17 AdvanSix Resins & Chemicals LLC Branched amino acid surfactants for oil and gas production
CN115677521B (zh) * 2022-11-16 2024-02-02 迪嘉药业集团股份有限公司 一种高纯度沙库巴曲钙的制备方法
CN117447341B (zh) * 2023-09-06 2025-11-18 杭州国瑞生物科技有限公司 一种沙库巴曲缬沙坦钠中间体的精制方法
CN117756622A (zh) * 2023-12-21 2024-03-26 安徽皓元药业有限公司 一种沙库巴曲关键中间体的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5015793B2 (enExample) 1972-06-07 1975-06-07
DE3164237D1 (en) 1980-12-23 1984-07-19 Air Ind Thermo-electrical plants
FR2597100A1 (fr) 1986-01-21 1987-10-16 Nippon Shinyaku Co Ltd Derives du pyroglutamide
PH24872A (en) 1986-08-25 1990-12-26 Schering Corp (5r,6s,8r)-6-(-1-hydroxyethyl)-2-(3r-pyrrolidin-2-one-3-yl)thiopenem-3-carboxylic acid
JPH07103101B2 (ja) * 1989-07-24 1995-11-08 キッセイ薬品工業株式会社 ピログルタミン酸誘導体
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
US5250522A (en) * 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
EP0599512B1 (en) 1992-11-17 1999-03-24 Sankyo Company Limited Crystalline carbapenem derivative
ZA938438B (en) * 1992-11-17 1994-06-20 Sankyo Co Crystalline carbapenem derivative
US5550119A (en) 1995-03-02 1996-08-27 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives as ECE inhibitors
KR19990082639A (ko) * 1996-02-19 1999-11-25 미즈노 마사루 당뇨병 치료제
US6420415B1 (en) * 1998-09-21 2002-07-16 Takeda Chemical Industries, Ltd. Thiol compounds, their production and use
PT1467728E (pt) 2002-01-17 2007-11-14 Novartis Ag Composições farmacêuticas compreendendo valsartan e inibidores da nep
ES2348534T3 (es) 2002-03-29 2010-12-09 Senju Pharmaceutical Co., Ltd. Derivador de hidroximordolinona y uso medicinal del mismo.
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US7671225B2 (en) 2004-05-07 2010-03-02 Umicore Ag & Co. Kg Ferrocenyl ligands for homogeneous, enantioselective hydrogenation catalysts
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
EP1903027A1 (en) 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
BRPI0806700A8 (pt) * 2007-01-12 2019-01-22 Novartis Ag processo

Similar Documents

Publication Publication Date Title
JP2010515698A5 (enExample)
JP2009120624A5 (enExample)
JP2013514257A5 (enExample)
JP2012517962A5 (enExample)
JP2008290071A5 (enExample)
JP2012111953A5 (enExample)
JP2013512223A5 (enExample)
JP2012516292A5 (enExample)
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
JP2010519270A5 (enExample)
JP2014513036A5 (enExample)
JP2010528132A5 (enExample)
JP2009544651A5 (enExample)
JP2010520214A5 (enExample)
JP2013506729A5 (enExample)
JP2013500200A5 (enExample)
JP2010285401A5 (enExample)
WO2011126245A3 (en) Novel method of preparing vanadosilicate molecular sieve and novel vanadosilicate molecular sieve
JP2014527200A5 (enExample)
JP2010053171A5 (enExample)
DE602006009789D1 (de) Acetylenderivate
JP2014000568A5 (enExample)
MY151228A (en) Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same
JP2010139756A5 (enExample)
JP2010282728A5 (enExample)